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Abstract
Background. Gliomas are the most common type of malignant brain and other CNS tumors, accounting for 80.8%
of malignant primary brain and CNS tumors. They cause significant morbidity and mortality. This study investigates the intersection between age and sex to better understand variation of incidence and survival for glioma in
the United States.
Methods. Incidence data from 2000 to 2017 were obtained from CBTRUS, which obtains data from the NPCR and
SEER, and survival data from the CDC’s NPCR. Age-adjusted incidence rate ratios (IRR) per 100 000 were generated to compare male-to-female incidence by age group. Cox proportional hazard models were performed by age
group, generating hazard ratios to assess male-to-female survival differences.
Results. Overall, glioma incidence was higher in males. Male-to-female incidence was lowest in ages 0-9 years
(IRR: 1.04, 95% CI: 1.01-1.07, P = .003), increasing with age, peaking at 50-59 years (IRR: 1.56, 95% CI: 1.53-1.59, P <
.001). Females had worse survival for ages 0-9 (HR: 0.93, 95% CI: 0.87-0.99), though male survival was worse for
all other age groups, with the difference highest in those 20-29 years (HR: 1.36, 95% CI: 1.28-1.44). Incidence and
survival differences by age and sex also varied by histological subtype of glioma.
Conclusions. To better understand the variation in glioma incidence and survival, investigating the intersection of
age and sex is key. The current work shows that the combined impact of these variables is dependent on glioma
subtype. These results contribute to the growing understanding of sex and age differences that impact cancer incidence and survival.
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Importance of the intersection of age and sex to
understand variation in incidence and survival for
primary malignant gliomas

Wang et al. Age and sex intersection in glioma incidence and survival

2. Female survival is worse in children 0-9 years but worse for males at all
other ages in primary gliomas.

Importance of the Study
Age and sex differences in incidence and survival for
primary malignant gliomas are well documented, independently. However, in order to better understand this
differences, analysis of the intersection of these 2 variables are key. The current work shows that age and sex
interact and influence glioma incidence and survival.
Males had significantly higher incidence rates overall,
and by most glioma subtypes, as compared to females
for all age groups. Male-to-female incidence was

Gliomas are tumors that arise from glial or precursor
cells and include astrocytoma, oligodendroglioma,
ependymoma, and other rare histologies.1 Gliomas are the
most common type of primary malignant brain and other
CNS tumor, accounting for approximately 25.1% of all primary brain and other CNS tumors and 80.8% of malignant
brain and other CNS tumors, and cause significant morbidity and mortality.1 The most commonly occurring primary malignant brain and other CNS tumor is glioblastoma
multiforme (GBM), accounting for the majority of gliomas
(57.7%) and comprising 14.5% of all tumors and 48.6% of
malignant tumors.1
Age is a key factor associated with incidence and survival
for all cancers and therefore is also an important factor in
the incidence and survival of gliomas.2 Gliomas are more
common in older adults, and peak in incidence between
the ages of 45 and 65 years old.3 Despite this, gliomas are
one of the most common solid tumor types in children and
account for approximately 45.5% of tumors in children and
adolescents age 0-19 years.1 Studies have shown that the
median age for diagnosis of high-grade glioma is higher in
females as compared to males.4 Interest in sex differences
in cancer has grown in recent years,5–8 especially now that
all National Institutes of Health (NIH) grants require an assessment of sex as a biological variable.9 Population-based
studies demonstrate that the incidence of gliomas varies
significantly by sex, with males having a 30%-50% higher
incidence for most glioma subtypes.10 In addition, a recent
study showed that among patients diagnosed with highgrade gliomas, there were significantly more female longterm survivors, with mean survival being 742 vs 628 days
(P = .03).4
Age or sex differences in incidence and survival for primary malignant gliomas are now well validated.1,5–8,11
While differences in survival and incidence based on sex
and age have been studied individually, there have been
no studies looking at the intersection of the 2 key variables
and their interactive role on incidence and survival for

lowest in children but increased into adulthood. Males
with malignant gliomas also had significantly higher
risk of death as compared to females, which differed
by age group. These results contribute to the growing
understanding and impact that both sex and age have
on cancer incidence and survival. Identifying disadvantaged sex and age groups is critical in influencing further research, and in developing individual care plans
for patients with these lethal tumors.

gliomas. This study investigates the intersection between
age and sex to better understand the variation of incidence
and survival for glioma in the United States. Identifying
disadvantaged sex and age groups is critical to providing
individualized care for these devastating tumors.

Methods
Data Sources
Incidence data. Incidence data were obtained for the
years 2000-2017 from the Central Brain Tumor Registry
of the United States (CBTRUS), which receives data in
collaboration with the Centers for Disease Control and
Prevention’s (CDC) National Program of Cancer Registries
(NPCR) and the National Cancer Institute’s (NCI) Survival
Epidemiology and End Results Program (SEER).12 This is
the largest population-based registry focused exclusively
on primary brain and other central nervous system tumors
in the United States, covering the entire US population.1

Survival data. Overall survival data from 2001 to 2016
used for analysis were obtained from the NPCR.13 This
dataset provides population-based information for 93.6%
of the US population and is a subset of the data used for
the incidence calculations. Overall survival information is
derived from both active and passive follow-up.

Selection Criteria
Patients with primary brain and other CNS gliomas from
individuals with no prior cancer diagnosis who were either microscopically or radiographically confirmed were
included in the analysis. International Classification of
Diseases for Oncology, Third Edition (ICD-O-3) codes were
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Statistical Analysis
The average annual age-adjusted incidence rates (AAIR)
and 95% confidence intervals (95% CI) were estimated per
100 000 population using the methodology described in
Tiwari et al.15 All rates were age-standardized to the 2000
US population and are reported per 100 000 population.
We used 10-year age interval to create age groups (0-9,
10-19, 20-29, 30-39, 40-49, 50-59, 60-69, 70-79, and 80 years
and older) based on age at primary cancer diagnosis. Ageadjusted incidence rate ratios (IRR) for sex (male:female)
with 95% CI were also generated from these standardized
rates. For incidence data, counts and rates are not presented when fewer than 16 cases were reported for the
specific category, or where the inclusion of the count and
rate would allow for back-calculation of suppressed values.
For example, if the remaining cells in a category can be
used to calculate the value of a suppressed cell (n < 16), an
additional cell will be suppressed.
Survival differences were assessed using age-stratified
Cox proportional hazards models, to generate hazard
ratios (HRs) with 95% CIs of male vs female by age group.
Both AAIRs/IRRs and HRs were estimated for overall
gliomas, and separately for anaplastic oligodendroglioma,
anaplastic oligodendroglioma, diffuse astrocytoma, GBM,
and oligodendroglioma. Survival time was recorded in
months and was defined from the date of diagnosis to the
date of death or last known contact. The Cox proportional
hazards assumption was tested for survival models, and
no variables were found in violation. For survival data,
counts and rates are not presented when fewer than 20
events were reported for the specific category. Additional
Cox proportional hazards models were assessed on a
subset of patients who had received a gross total resection (SEER Site-Specific Surgery Codes: 30, 55) to adjust
for surgical treatment.
Chi-square tests were performed to assess demographic
and histology differences between males and females.
All analyses were performed using R (version 4.0.4) and
SEER*Stat 8.3.8.

Results
Descriptive Statistics
Overall, from 2000 to 2017, there were 294 886 patients
with primary malignant brain and other CNS gliomas
(Table 1). Of these, 130 051 (44.1%) were females and
164 835 (55.9%) were males. Overall, malignant glioma incidence was highest in the age group 60-69 years (60 198
cases, 20%), and lowest in 10-19 years (15 005 cases, 5.1%).
Age distribution differed significantly between males and
females (P < .001). Additional patient characteristics by
sex are presented in Table 1. GBM was the most predominant histology with 161 237 (55%) of the overall patients.
Among GBM, 68 759 (53%) were female, and 92 478 (56%)
were male.

Incidence
The AAIRs and IRRs of male vs female with 95% CIs by age
groups for all gliomas are displayed in Figures 1 and 2 and
Supplementary Table 1. The age group with the highest
AAIR for overall patients was 70-79 years (AAIR = 14.36,
95% CI: 14.23-14.5), followed by 60-69 years (AAIR = 11.98,
95% CI: 11.88-12.08) and 80+ years (AAIR = 10.86, 95% CI:
10.71-11). Overall, the incidence of glioma in all age groups
was higher in males. The age group with the smallest IRR
was 0-9 years (IRR = 1.04, 95% CI: 1.01-1.07, P = .003). The
IRR continued to increase with age, peaking at 50-59 years
old (IRR = 1.56, 95% CI: 1.53-1.59, P < .001) (Figure 2).
AAIRs and IRRs by sex and age are also shown for the
following glioma subtypes: anaplastic oligodendroglioma,
anaplastic oligodendroglioma, diffuse astrocytoma, GBM,
and oligodendroglioma (Figures 1 and 2, Supplementary
Table 3). For males, the age group with the highest AAIR
for anaplastic astrocytoma, diffuse astrocytoma, and
GBM was 70-79 years. In males, the highest incidence for
anaplastic oligodendroglioma and oligodendroglioma occurred earlier, at ages 50-59 and 30-39 years, respectively.
Females showed peaks in incidence that differed from
males for anaplastic oligodendroglioma and oligodendroglioma, with the highest AAIR occurring between ages
40-49 years. In addition, for anaplastic oligodendroglioma
and diffuse astrocytoma, the corresponding IRRs of all age
groups were significantly higher in males. For anaplastic
astrocytoma and GBM, the corresponding IRRs of all age
groups were significant for higher incidence in males except for age 0-9 years.

Survival
Cox proportional hazards models were used to generate
HRs of male vs female sex with 95% CIs by age groups
overall are shown in Figure 3 and Supplementary Table 2.
The HR for male sex for those 0-9 years old was 0.93 (95%
CI: 0.87-0.99), showing that females in this age group with
malignant gliomas were significantly at higher risk of
death. For all other age groups (10-69 years), male sex was
associated with increased hazard of death. Patients age
10-19 years or 20-29 years had the highest HR for male sex
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used for identification, and tumors were defined according
to the CBTRUS histologic grouping scheme.1 Only malignant cases (ICD-O-3 behavior code of 3) were included in
this analysis. ICD-O-3 codes used are as follows: anaplastic
astrocytoma (ICD-O-3 code 9401), anaplastic oligodendroglioma (9451, 9460), diffuse astrocytoma (9400, 9410,
9411, 9420), ependymal tumors (9391, 9392, 9393), GBM
(9440, 9441, 9442), glioma malignant, not otherwise specified (NOS) (9380), neuronal and mixed neuronal-glial
tumors (8680, 8693, 9505, 9522, 9523), oligoastrocytic tumors (9382), oligodendroglioma (9450), other neuroepithelial tumors (9423, 9430), pilocytic astrocytoma (9421,
9425), and unique astrocytoma variants (9381, 9424).
While pilocytic astrocytoma is not a clinically malignant
tumor, cancer registries have historically coded it as malignant (ICD-O-3 behavior code of 3). CBTRUS therefore
reports pilocytic astrocytoma as malignant per guidelines
set by the International Agency for Research on Cancer
(IARC) and International Association of Cancer Registries
(IACR).14
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Overall, N = 294 886a

Female, N = 130 051a

Male, N = 164 835a

P Valueb

Age group, yr
0-9

19 707 (6.7%)

9425 (7.2%)

10 282 (6.2%)

10-19

15 005 (5.1%)

7090 (5.5%)

7915 (4.8%)

20-29

16 945 (5.7%)

7541 (5.8%)

9404 (5.7%)

30-39

24 595 (8.3%)

10 472 (8.1%)

14 123 (8.6%)

40-49

36 206 (12%)

14 678 (11%)

21 528 (13%)

50-59

56 027 (19%)

22 586 (17%)

33 441 (20%)

60-69

60 198 (20%)

25 524 (20%)

34 674 (21%)

70-79

44 959 (15%)

21 121 (16%)

23 838 (14%)

80+

21 244 (7.2%)

11 614 (8.9%)

9630 (5.8%)

White

262 643 (89%)

115 239 (89%)

147 404 (89%)

Black

20 275 (6.9%)

9509 (7.3%)

10 766 (6.5%)

<.001

Race

American Indian/Alaska Native

1531 (0.5%)

687 (0.5%)

844 (0.5%)

Asian or Pacific Islander

5859 (2.0%)

2714 (2.1%)

3145 (1.9%)

Other/Unknown

4578 (1.6%)

1902 (1.5%)

2676 (1.6%)

266 735 (90%)

117 238 (90%)

149 497 (91%)

28 151 (9.5%)

12 813 (9.9%)

15 338 (9.3%)

19 983 (6.8%)

8853 (6.8%)

11 130 (6.8%)

<.001

Ethnicity
Non-Hispanic or Latino
Hispanic or Latino

<.001

Histology
Anaplastic astrocytoma
Anaplastic oligodendroglioma

6218 (2.1%)

2763 (2.1%)

3455 (2.1%)

Diffuse astrocytoma

27 519 (9.3%)

12 144 (9.3%)

15 375 (9.3%)

Ependymal tumors

13 053 (4.4%)

6211 (4.8%)

6842 (4.2%)

161 237 (55%)

68 759 (53%)

92 478 (56%)

21 718 (7.4%)

10 775 (8.3%)

10 943 (6.6%)

2698 (0.9%)

1109 (0.9%)

1589 (1.0%)

8481 (2.9%)

3606 (2.8%)

4875 (3.0%)

14 001 (4.7%)

6226 (4.8%)

7775 (4.7%)

Glioblastoma
Glioma malignant, NOS
Neuronal and mixed neuronal glial tumors
Oligoastrocytic tumors
Oligodendroglioma
Other neuroepithelial tumors
Pilocytic astrocytoma
Unique astrocytoma variants

215 (<0.1%)

147 (0.1%)

<.001

68 (<0.1%)

17 594 (6.0%)

8450 (6.5%)

9144 (5.5%)

2169 (0.7%)

1008 (0.8%)

1161 (0.7%)

Surgery type
No surgery

114 752 (39%)

52 295 (40%)

62 457 (38%)

Partial or subtotal resection

60 071 (20%)

25 458 (20%)

34 613 (21%)

Gross total resection

74 889 (25%)

32 395 (25%)

42 494 (26%)

Unknown

45 174 (15%)

19 903 (15%)

25 271 (15%)

<.001

Abbreviations: CDC, Centers for Disease Control and Prevention; NCI, National Cancer Institute; NOS, not otherwise specified.
an (%).
bPearson’s chi-square test.

  
compared to other age groups (20-29 years HR: 1.36, 95%
CI: 1.28-1.44; 30-39 years HR: 1.29, 95% CI: 1.23-1.35).
Subtype-specific HRs by age groups were also generated
(Figure 3, Supplementary Table 4). The HR for male was
highest in age groups 30-39 and 50-59 years oligodendroglioma and anaplastic oligodendroglioma, respectively.

Male HR was significantly increased in age groups 20-29,
30-39, 40-49, and 50-59 years for anaplastic astrocytoma,
diffuse astrocytoma, GBM, with the exception of GBM patients in the 30- to 39-year age group.
In order to assess the impact of extent of resection on
survival differences between male and female by age
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Overall
0.8

0.20

0.6

0.15

10

0.2

0.05

0.0

0.00

0–
10 9
–1
20 9
–2
30 9
–
40 39
–4
50 9
–5
60 9
–
70 69
–7
9
80
+

0

0.10

0–
10 9
–1
20 9
–2
30 9
–
40 39
–4
50 9
–5
60 9
–
70 69
–7
9
80
+

5

0.4

Diffuse astrocytoma

0–
10 9
–1
20 9
–2
30 9
–
40 39
–4
50 9
–5
60 9
–
70 69
–7
9
80
+

15

Anaplastic oligodendroglioma

Anaplastic astrocytoma

Glioblastoma

Oligodendroglioma

1.00
0.75

10

0.4

5

0.2

0

0.0

0.50

0–
10 9
–1
20 9
–2
30 9
–
40 39
–4
50 9
–5
60 9
–
70 69
–7
9
80
+

0–
10 9
–1
20 9
–2
30 9
–
40 39
–4
50 9
–5
60 9
–
70 69
–7
9
80
+

0.00

0–
10 9
–1
20 9
–2
30 9
–
40 39
–4
50 9
–5
60 9
–
70 69
–7
9
80
+

0.25

Age group
Male

Female

Fig. 1 Age-adjusted incidence rate by sex for primary, malignant gliomas by age groups (CBTRUS: Data provided by CDC’s National Program of
Cancer Registries and NCI’s Surveillance, Epidemiology and End Results Program, 2000-2017). Abbreviations: CDC, Centers for Disease Control
and Prevention; NCI, National Cancer Institute.
  

group and by histology, we also looked at the subset
of patients who had complete extent of resection data
(n = 215 944 (87.63% of patients included in survival analysis). Overall, 64 087 (29.68%) patients had gross total resection, 51 771 (23.97%) had subtotal or partial resection,
and 100 086 (46.35%) had no surgery. The survival trends
among male vs female by age groups and histology were
not significantly different after adjusting for extent of resection in the multivariable Cox model (Supplementary
Figure 1).

Discussion
In this study, we provide evidence to show that incidence
and overall survival of primary malignant gliomas vary
by sex and age. To our knowledge, this is the first analysis
investigating the intersection of sex and age to better understand variation in incidence and survival for glioma. We
found that the incidence of glioma was higher for males
across all age groups and in general males had a higher
risk of death as compared to females.
Gliomas are the most common malignant brain tumor
and can cause significant morbidity and mortality. For

example, median survival of GBM cases diagnoses from
2001 to 2016 in the United States was only 8 months.
Anaplastic ependymoma had a reported median survival
of 18 months and 3 years for diffuse astrocytoma.1 These
tumors are often diagnosed through either neuroimaging
techniques, such as CT or MRI scans, and pathologic confirmation from tumor tissue received at biopsy or resection.16 The use of molecular biomarkers is also used to
help differentiate between glioma types, such as between
oligodendrogliomas and astrocytomas, and to identify clinically significant subgroups within certain histologies, such
as glioblastoma vs anaplastic astrocytoma.16 Molecular
biomarker data are not currently available in tumor registries, such as CBTRUS, as tumor registries did not collect
the 2016 WHO Classification biomarkers until 2018.17 This
information will be available in future data releases.
Age is a well-validated independent factor associated
with incidence and survival for all cancers.1 Some cancers,
including brain and other CNS tumors and leukemia, are
common in children while others are more common in
adults.18 Specific glioma subtypes are well documented
to be quite common in childhood and very rare in adulthood and vice versa.1 Age is one of the primary risk factors
for cancer, with individuals ≥65 years of age accounting
for 60% of newly diagnosed malignancies and 70% of all
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1.5

1.5

1.5

1.0

1.0

1.0

0–
10 9
–1
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30 9
–3
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–
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–
60 59
–6
70 9
–7
9
80
+

2.0

0–
10 9
–1
20 9
–2
30 9
–3
40 9
–
50 49
–
60 59
–6
70 9
–7
9
80
+

2.0

0–
10 9
–1
20 9
–2
30 9
–3
40 9
–
50 49
–
60 59
–6
70 9
–7
9
80
+

2.0

Glioblastoma

Diffuse astrocytoma

Oligodendroglioma
2.0

1.5

1.5

1.5

1.0

1.0

1.0

Age group

0–
10 9
–1
20 9
–2
30 9
–3
40 9
–
50 49
–
60 59
–6
70 9
–7
9
80
+

2.0

0–
10 9
–1
20 9
–2
30 9
–3
40 9
–
50 49
–
60 59
–6
70 9
–7
9
80
+

2.0

0–
10 9
–1
20 9
–2
30 9
–3
40 9
–
50 49
–
60 59
–6
70 9
–7
9
80
+

Age-adjusted incidence rate ratio per 100 000 (male:female)
Higher for female <-> Higher for male

Anaplastic oligodendroglioma

Fig. 2 Age-adjusted incidence rate ratio (male vs female) with 95% CI for primary, malignant gliomas by age groups (CBTRUS: Data provided
by CDC’s National Program of Cancer Registries and NCI’s Surveillance, Epidemiology and End Results Program, 2000-2017). Abbreviations: CDC,
Centers for Disease Control and Prevention; NCI, National Cancer Institute.
  

cancer-related deaths.19,20 Previous studies highlighted an
age-adjusted cancer mortality rate for persons ≥65 at ~16
times higher than the mortality rate for those <65.20,21
Aging is a complex process that could affect cancer
risk through multiple mechanisms. Among these, are
the effects of aging on nearly all aspects of the immune
system,20,22 which has been strongly implicated in cancer
prevention, development, and defense.20,23 Aging negatively impacts apoptotic cell clearance,24 the numbers of
naïve T cells,25 and the wound healing response.26 Neuroimmune interactions are also affected by aging in the
brain,20,27 and research has shown that aging progressively
suppresses normal immunosurveillance and decreases
immunotherapeutic efficacy against malignant glioma.20
Immunosuppression increases in the brain with advanced
age, and there is an inhibition of anti-glioma immunity in
older adults.28 These results suggest that cellular immunity may play an age-dependent role in the development of
brain and other CNS tumors and should be integrated with
emerging evidence for sex differences in immune suppression and tumor microenvironment interactions.29,30
Studies have shown that the incidence of primary brain
and other CNS tumors increases with age, and our updated study further confirms such a trend for primary

brain and other CNS glioma as well as its association
with sex.1,31 An increasing incidence of primary malignant
gliomas with increasing age likely suggests that malignant transformation of these cells is a chronic process with
sequential changes of genetic alteration occurring with
age.1,32 Glioma incidence is at its nadir between the ages
of 10-19 and peaks at 70-79 years, which suggests that both
genetic and environmental factors may have a role, with
genetic factors playing a relatively larger role in early life
risk and the environment being the larger contributor for
older age groups.31,32 Analyzing these patterns of glioma
incidence and survival with age and sex allows us to evaluate these patterns by age and generate hypotheses about
their etiopathogenesis.
Sexual differentiation during development results in
sex differences in cellular and systems biology,6,33,34 including sexually dimorphic traits such as body size,
metabolism, and disease risk.35–38 Sex differences are
evident in brain size, rates of myelination, and risk for
neurodevelopmental disorders and psychiatric diseases.39–41 In cancer, significant sex differences exist in
incidence of most tumor types that arise in both sexes,
suggesting fundamental biological differences between
males and females impact cancer incidence.5 Historically,
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sex-based differences in complex diseases have been
understudied. Multiple studies have been conducted to
examine the potential role of either endogenous or exogenous hormone exposures and risk of brain and other CNS
tumors, with mixed results.6 Prior research has shown
that overall incidence of cancer has increased in males42
including GBM.8,43 Females with GBM have a significant
overall survival advantage that is further enhanced after
adjustment for known independent prognostic factors
such as age, Karnofsky performance status (KPS), extent
of resection, and receipt of standard therapy.8 Though,
this is not seen for lower grade glioma.44
Sex differences in glioma incidence may be partially due
to the genetic differences between males and females.10
A sex-specific genome-wide association study identified
3 sex-specific glioma risk loci (7p11.2, 8q24.21, 3p21.31).10
DNA methylation differences between males and females
in 4 glioma molecular subtypes suggest an important sexspecific role for DNA methylation in epigenetic regulation
of gliomagenesis.45 In addition, research has shown that
the standard treatment for GBM might be more effective
for females than for males.46 With respect to the molecular
basis of this sex difference in treatment response, maleand female-specific gene expression clusters were identified that uncovered long-term survival signatures, with
male long-term survivors having alterations in cell cycle
genes compared to female long-term survivors that had

alterations in integrin signaling genes.7 However, our understanding of the many factors that determine sex-based
differences in complex disease remains limited. Using
population-based cancer registry data to better understand
age/sex variation in incidence and survival is critical to
moving forward our understanding of the intersection of
these key variables and the role they play in tumorigenesis
and treatment.
There is growing information on the role of sex and age
on cancer incidence and survival. Most prior research has
analyzed the impact of age and sex separately. The aim
of our study was to examine the interaction between age
and sex influence incidence and survival of gliomas in the
United States. We found that glioma incidence is higher in
males and adults, accurately aligning with the previously
stated literature. Importantly, we found that this maleto-female difference in incidence was influenced by age.
Male-to-female IRR of glioma was lowest in those 0-9 years
old (IRR = 1.04, 95% CI: 1.01-1.07, P = .003), and increased
over time, with the highest IRR present in those 50-59 years
old (IRR = 1.56, 95% CI: 1.53-1.59, P < .001). Additionally, we
found age and sex differences to be present in glioma survival as well, where females had overall worse survival in
ages 0-9 years (HR: 0.93, 95% CI: 0.87-0.99), but better survival in all other age groups. These findings in this study
imply an interaction between age and sex in glioma incidence and survival, the first study to present these findings
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